Notably, KSR2 has also been linked to MAPK pathway reactivation and resistance to BRAF+MEK inhibition in melanoma cells, thus suggesting that the roles of KSR1 or KSR2 in modulating the response to KRAS/MAPK pathway inhibition may have been underestimated [43]. The gene discussed is KRAS; the disease is melanoma.